Interim Report January – March 2022
Decision on marketing approval for lecanemab is approaching
Presentations
Kempen Life Sciences Conference
Gunilla Osswald, CEO, presented BioArctic at the Kempen Life Sciences Conference in Amsterdam
BioArctic and Eisai presented latest data regarding lecanemab at the AD/PDTM 2022 conference
BioArctic and its partner Eisai presented data on the drug candidate lecanemab (BAN2401) – an investigational anti-amyloid-beta (Aβ) protofibril antibody being developed for the treatment of ...
Carnegie Healthcare Seminar
Gunilla Osswald, CEO, presented BioArctic at the Carnegie Healthcare Seminar in Stockholm
BioCapital Europe
Gunilla Osswald, CEO, presented BioArctic at the BioCapital Europe Conference in Amsterdam
Erik Penser Healthcare day
Oskar Bosson, VP Communications & Investor Relations, presented at the Erik Penser Healthcare day in Stockholm
Full Year Report 2021
A time of hope for Alzheimer’s patients
SEB Nordic Healthcare Seminar
Gunilla Osswald, CEO, presented BioArctic at the SEB Nordic Healthcare Seminar in Stockholm
New company presentation
BioArctic has updated its company presentation following the CTAD congress and recent news flow.
New data on lecanemab presented at the CTAD Alzheimer conference
BioArctic and partner Eisai held several oral presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 9-12, 2021, revealing new data on lecanemab ...
The Swedish-American Life Science Summit 2021
Gunilla Osswald, CEO, presented BioArctic at the Swedish-American Life Science Summit (SALSS) in Stockholm
Interim report January – September 2021
Eisai initiates Biologics License Application of lecanemab in the US earlier than expected
Redeye Neurology Seminar CNS
Gunilla Osswald, CEO, presented BioArctic at the Redeye Neurology Seminar CNS in Stockholm.
International Congress of Parkinsons disease and movement disorders® (MDS)
BioArctics Head of Research, Johanna Fälting, presented at the International Congress of Parkinsons disease and movement disorders® (MDS).
Pareto Healthcare Conference
Gunilla Osswald, CEO, presented BioArctic at the Pareto Healthcare Conference in Stockholm.
Nordea Small and Mid Cap Days
Gunilla Osswald, CEO, presented BioArctic at the Nordea Small and Mid Cap Days in Stockholm.
Eisai presented latest data from the lecanemab clinical program at AAIC 2021
BioArctic AB’s partner Eisai held several presentations at the Alzheimer’s Association International Conference (AAIC) in Denver, Colorado July 26 to 30, 2021. The presentations included the ...
Interim report January – June 2021
FDA grants Breakthrough Therapy designation for lecanemab
ABGSC Life Science Summit 2021
Gunilla Osswald, CEO, presented BioArctic at the ABGSC Life Science Summit in Stockholm.
Aktiedagen Stockholm
On May 4 at 9:30 CET, BioArctic’s VP Communications and Investor Relations, Oskar Bosson, presented BioArctic at a Capital Markets Day hosted by Aktiespararna. The presentation ...
Interim Report January – March 2021
New data continues to strengthen lecanemab
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021
BioArctic AB and its partner Eisai presented new data on the drug candidate lecanemab (BAN2401) at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and ...
Full Year Report January – December 2020 – Presentation
New data provides further support for BAN2401 (lecanemab)
Erik Penser Bank Bolagsdag
On November 25 at 10:05 CET, BioArctic's VP Communications and Investor Relations, Oskar Bosson, presented BioArctic at a Capital Markets Day hosted by Erik Penser Bank. ...
Avanza’s Capital Markets Day 2020
On November 18 at 08:00 CET, BioArctic's CEO, Gunilla Osswald, presented BioArctic at Avanza's Capital Markets Day 2020. The presentation was broadcasted live via this link ...
Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
BioArctic's partner Eisai presented new data on the drug candidate BAN2401 (lecanemab) at the Clinical Trials on Alzheimer’s Disease conference (CTAD), November 4-7. The presentations included ...
Interim Report January – September 2020
An additional Phase 3 study in Alzheimer’s disease
Pareto Healthcare Conference
Gunilla Osswald, CEO, presented BioArctic at the Pareto Healthcare Conference in Stockholm.
Alzheimer’s Association International Conference® 2020 (AAIC®)
BioArctic’s partner Eisai presented the latest data from the open-label extension of the Phase 2b study with the investigational BAN2401 in early Alzheimer’s disease. The preliminary ...
Interim Report for the period January – June 2020
Continued performance according to plan
Redeye Growth Day – presentation and interview
Gunilla Osswald, CEO, presented BioArctic at the Redeye Growth Day in Stockholm. Redeye interviewed Gunilla Osswald, CEO, and talked about innovation, sustainability and how BioArctic can ...
ABGSC – Life Science Summit
Gunilla Osswald, CEO, presented BioArctic at the ABGSC Life Science Summit in Stockholm.
Interim Report January – March 2020 – Presentation
Operations performing according to plan
Stockholm Corporate Finance Life Science Seminar
Gunilla Osswald, CEO, presented BioArctic and answered questions at the Stockholm Corporate Finance Life Science Seminar in Stockholm, Sweden. Link to BioArctic presentation and question and ...
9th Annual SVB Leerink Global Healthcare Conference in New York
Gunilla Osswald, CEO, presented BioArctic at 9th Annual SVB Leerink Global Healthcare Conference in New York.
Full Year Report January – December 2019 – Presentation
Enhanced project portfolio from a successful year
DNB Nordic Healthcare conference
Gunilla Osswald, CEO, presented BioArctic at DNB Nordic Healthcare conference in Oslo.
Clinical Trials in Alzheimer’s Disease (CTAD) conference
Presentations related to BAN2401 were given at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held December 4-7 in San Diego, USA. BioArctic’s partner Eisai presented ...
Nordea Innovation Seminar
Gunilla Osswald, CEO, presented BioArctic at Nordea Innovation Seminar in Stockholm.
Interim Report January – September 2019 – Presentation
BioArctic: Strong continued progress year to date
Redeye Neurology Seminar
Gunilla Osswald, CEO, presents BioArctic and participates in a panel discussion at the Redeye Neurology Seminar in Stockholm, Sweden. BioArctic presentation (in Swedish) Panel discussion (in ...
Alzheimer’s Association International Conference 2019 in Los Angeles
The antibody BAN2401 was designed and generated to selectively target toxic protofibrils and oligomers, soluble aggregated forms of amyloid-beta.
Interim Report January – June 2019 – Presentation
BioArctic: Significant progress in the projects and additional milestone payment
Redeye – CEO interview
Get to know BioArctic’s CEO Gunilla Osswald, an interview by Redeye’s Equity Analyst Eddie Palmgren. Video (in Swedish).
Redeye Growth Day Presentation and Interview with EFN
Gunilla Osswald, CEO, presented BioArctic at the Redeye Growth Day in Stockholm, Sweden. Video (in Swedish) EFN Interview (in Swedish) https://www.efn.se/bors-finans/biorctic-ser-framgangar-inom-samtliga-omraden/
Jefferies 2019 Global Healthcare Conference
Gunilla Osswald, CEO, presented BioArctic at Jefferies 2019 Global Healthcare Conference in New York.
Interim Report January – March 2019 – Presentation
BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease. Phase 1-study with ABBV-0805 in the Parkinson program started
BioStock Live panel discussion “The Alzheimer Challenge”
Watch the replay of the panel discussion on April 29th at BioStock on "The Alzheimer Challenge" with BioArctic's CEO, Gunilla Osswald.
Redeye – CEO presentation and interview
Gunilla Osswald, CEO, presented BioArctic at Redeye’s lunch meeting in Stockholm, Sweden, on April 3.
Carnegie Nordic Healthcare Seminar
Gunilla Osswald, CEO, presented BioArctic at the Carnegie Nordic Healthcare Seminar in Stockholm, Sweden.
Full Year Report January – December 2018 – Presentation
BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio.
Redeye – CEO interview
BioArctic announced on February 4 that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease. Interview with CEO Gunilla Osswald here.
Aktiespararna Life Science in Stockholm
Gunilla Osswald, CEO, presented BioArctic at Aktiespararna’s Life Science evening event in Stockholm, Sweden, on January 21.
Interview with Gunilla Osswald, CEO
Gunilla Osswald, CEO, was interviewed by Klas Palin, life science analyst at Redeye, in Stockholm on December 14, 2018.
DNB’s Annual Nordic Healthcare Conference in Oslo
Gunilla Osswald, CEO, presented BioArctic at DNB’s 9th Nordic Healthcare Conference in Oslo, Norway, on December 12.
Nordea Tech & Medtech/Life Science Seminar in Stockholm
Gunilla Osswald, CEO, presented BioArctic at the Nordea Tech & Medtech/Life Science Seminar in Stockholm, Sweden, on November 27.
Stora Aktiedagen in Stockholm
Gunilla Osswald, CEO, presented BioArctic at the “Stora Aktiedagen” in Stockholm, Sweden, on November 26.
Jefferies 2018 London Healthcare Conference
Gunilla Osswald, CEO, presented BioArctic at Jefferies 2018 London Healthcare Conference.
Biotech and Money in London
Gunilla Osswald, CEO, presented BioArctic at Biotech and Money, Investival Showcase, on November 13 in London.
Interim Report January – September 2018 – Presentation
BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects.
Redeye CNS Biotech Seminar
Gunilla Osswald, PhD, CEO, presents BioArctic at Redeye CNS Biotech Seminar in Stockholm, Sweden.
Interim Report January – June 2018 – Presentation
Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease
Redeye Growth Day
Gunilla Osswald, PhD, CEO, presents BioArctic at Redeye Growth Day in Stockholm, Sweden.
Annual General Meeting 2018
Presentation at BioArctic AB's Annual General Meeting 2018.
Interim Report January – March 2018 – Presentation
Continued progress of the project portfolio.
Carnegie Healthcare Seminar 2018
Gunilla Osswald, PhD, CEO, presented BioArctic at the Carnegie Healthcare Seminar 2018 on March 14 in Stockholm, Sweden.
11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech & Pharma Industry, Zurich, Switzerland
Gunilla Osswald, CEO of BioArctic AB, presented the company at the 11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech ...
Full Year Report January – December 2017 – Presentation
Successful IPO and continued positive result for BioArctic
DNB Nordic Healthcare Conference
Gunilla Osswald, CEO of BioArctic AB, presented the company at DNB Nordic Healthcare Conference in Oslo, Norway, on December 14, 2017.
Carnegie Nordic Healthcare Day in New York
Gunilla Osswald, CEO of BioArctic AB, presented the company at Carnegie Nordic Healthcare Day in New York on December 5, 2017.
Evercore ISI in New York
Gunilla Osswald, PhD, CEO, and Lars Lannfelt, Professor, MD, Senior Advisor and Co-Founder presented BioArctic at Evercore ISI in New York. The lunch meeting took place ...